Cost-effectiveness of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery

J. Slof, R. Díez Valle, J. Galván

Research output: Contribution to journalArticleResearchpeer-review

38 Citations (Scopus)


© 2013 Sociedad Española de Neurología. Objective: This study evaluates the cost-effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan®) in patients undergoing surgery for malignant glioma, in standard clinical practice conditions in Spain. Material and methods: Cost-effectiveness ratios were determined in terms of incremental cost per complete resection (CR) and incremental cost per additional quality-adjusted life year (QALY), based on data collected in the VISIONA observational study. Results: Incremental cost with 5-ALA versus conventional surgery using white light only amounts to € 4550 per additional CR achieved and € 9021 per QALY gained. A sensitivity analysis shows these results to be robust. Conclusion: Malignant glioma surgery guided by 5-ALA fluorescence entails a moderate increase in hospital costs compared to current surgical practice and can be considered a cost-effective innovation.
Original languageEnglish
Pages (from-to)163-168
Number of pages5
Issue number3
Publication statusPublished - Apr 2015


  • 5-aminolevulinic acid
  • Cost-effectiveness
  • Fluorescence-guided surgery
  • Glioblastoma
  • Malignant glioma


Dive into the research topics of 'Cost-effectiveness of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery'. Together they form a unique fingerprint.

Cite this